Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Goldstein

Showing results (501-510 of 518) with videos related to

Pageof 52
Sort By:
Journal for Immunotherapy of Cancer|October 2, 2021
Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity studyMarc Oliva, Douglas Chepeha, Daniel V Araujo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 15, 2022
Adjuvant <i>nab</i>-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III TrialMargaret A Tempero, Uwe Pelzer, Eileen M O'Reilly, et al.
Medrxiv : the Preprint Server for Health Sciences|May 20, 2024
Characterising the contribution of rare protein-coding germline variants to prostate cancer risk and severity in 37,184 casesJonathan Mitchell, Niedzica Camacho, Patrick Shea, et al.
Annals of Surgery|October 26, 2017
The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal AdenocarcinomaPaula Ghaneh, Jorg Kleeff, Christopher M Halloran, et al.
Cell Death & Disease|April 24, 2026
βIII-tubulin can act as a brake on extrinsic apoptosis in pancreatic cancerGeorge Sharbeen, John Kokkinos, Grace Schulstad, et al.
JAMA Oncology|March 5, 2026
Genomic Therapy Matching in Rare and Refractory CancersFrank P Lin, Subotheni Thavaneswaran, John P Grady, et al.
Nature Communications|February 19, 2025
Assessing the contribution of rare protein-coding germline variants to prostate cancer risk and severity in 37,184 casesJonathan Mitchell, Niedzica Camacho, Patrick Shea, et al.
Journal of the National Cancer Institute|December 5, 2013
Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trialWilliam Greenhalf, Paula Ghaneh, John P Neoptolemos, et al.
BMJ Open|October 3, 2019
The Upper Gastrointestinal Cancer Registry (UGICR): a clinical quality registry to monitor and improve care in upper gastrointestinal cancersAshika D Maharaj, Jennifer F Holland, Ri O Scarborough, et al.
The Lancet. Oncology|March 7, 2018
Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable diseaseEmil Ter Veer, L Bengt van Rijssen, Marc G Besselink, et al.
Pageof 52

Showing results (501-510 of 518) with videos related to

Sort By:
Pageof 52
Journal for Immunotherapy of Cancer|October 2, 2021
Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity studyMarc Oliva, Douglas Chepeha, Daniel V Araujo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 15, 2022
Adjuvant <i>nab</i>-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III TrialMargaret A Tempero, Uwe Pelzer, Eileen M O'Reilly, et al.
Medrxiv : the Preprint Server for Health Sciences|May 20, 2024
Characterising the contribution of rare protein-coding germline variants to prostate cancer risk and severity in 37,184 casesJonathan Mitchell, Niedzica Camacho, Patrick Shea, et al.
Annals of Surgery|October 26, 2017
The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal AdenocarcinomaPaula Ghaneh, Jorg Kleeff, Christopher M Halloran, et al.
Cell Death & Disease|April 24, 2026
βIII-tubulin can act as a brake on extrinsic apoptosis in pancreatic cancerGeorge Sharbeen, John Kokkinos, Grace Schulstad, et al.
JAMA Oncology|March 5, 2026
Genomic Therapy Matching in Rare and Refractory CancersFrank P Lin, Subotheni Thavaneswaran, John P Grady, et al.
Nature Communications|February 19, 2025
Assessing the contribution of rare protein-coding germline variants to prostate cancer risk and severity in 37,184 casesJonathan Mitchell, Niedzica Camacho, Patrick Shea, et al.
Journal of the National Cancer Institute|December 5, 2013
Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trialWilliam Greenhalf, Paula Ghaneh, John P Neoptolemos, et al.
BMJ Open|October 3, 2019
The Upper Gastrointestinal Cancer Registry (UGICR): a clinical quality registry to monitor and improve care in upper gastrointestinal cancersAshika D Maharaj, Jennifer F Holland, Ri O Scarborough, et al.
The Lancet. Oncology|March 7, 2018
Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable diseaseEmil Ter Veer, L Bengt van Rijssen, Marc G Besselink, et al.
Pageof 52